Assessment of the risk of tumor progression in different subtypes of breast cancer

Autor:	Liubov Yu Vladimirova, Valeria A. Bandovkina, Natalia D. Cheryarina, Elena A. Sheiko, Oleg I. Kit, Elena M. Frantsiyants, Aleksandr E. Lisutin, Anna E. Storozhakova, Evgeniya M. Nepomnyashchaya, Marina M. Sergeeva, Natalia Yu. Samaneva
Rok vydání:	2020
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry medicine.disease Tumor recurrence 03 medical and health sciences 0302 clinical medicine Breast cancer Tumor progression 030220 oncology & carcinogenesis Internal medicine medicine business 030215 immunology
Zdroj:	Web of Science
ISSN:	1527-7755 0732-183X
Popis:	e12551 Background: Breast cancer (BC) is still one of the main causes of death in women due to the tumor recurrence and/or resistance to anticancer therapy. The criteria to assess the risk of tumor progression in breast cancer after 2 chemotherapy cycles are required. The purpose of the study was to analyze blood levels of TGFβ, TGFR2, TNF, TNFα, TNFR1, TNFR2, MMP-9 and CD-44 in patients with various BC subtypes before and after 2 chemotherapy cycles. Methods: The study included 42 patients with various BC subtypes: luminal A, luminal B and triple-negative BC (TNBC). Levels of TGFβ, TGFR2, TNF, TNFR1, TNFR2, CD-44, MMP-9 were measured by ELISA in the blood of all patients prior to anticancer therapy and after 2 chemotherapy cycles. Statistical processing of results was performed using the Statistika 6.0 software by the Student’s t-test. Results: Levels of TGFβ, TGFR2, TNF, TNFα, TNFR1, TNFR2, CD-44, MMP-9 in patients with all BC subtypes were high before the treatment. After 2 chemotherapy cycles, the values decreased statistically significantly in all BC subtypes: CD-44 decreased by 25.2%, 30% and 54.7% in luminal A, luminal B and TNBC, respectively; TNFα – by 26.2%, 48.3% and 50.8%, respectively; TNFα-R1 – by 52.1%, 39.2% and 50.3% respectively; TNFα-R2 – by 31.7%, 32.8% and 41.9% respectively; MMP-9 – 35.3%, 32.6% and 43.3% respectively. The patients remained in remission for 3 years. When the levels were high or did not differ from initial values, the tumor progressed. Conclusions: We identified a set of criteria allowing with high probability to determine the growth and progression of tumors in various subtypes of breast cancer after two cycles of chemotherapy. A decrease in the levels of TGF-β, TNF, MMP-9, and CD-44 demonstrates remission; stabilization or increase of these indicators leads to further early progression of the disease.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc5047d432760bfbf7c6f234647d31b https://doi.org/10.1200/jco.2020.38.15_suppl.e12551 Zobrazit plný text záznamu